The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Study ID: NCT01134562
Brief Summary: The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Cypress, California, United States
, Shreveport, Louisiana, United States
, Houston, Texas, United States
, Brisbane, Queensland, Australia
, Melbourne, Victoria, Australia
Name: Gregory Bell, MD
Affiliation: KAI Pharmaceuticals
Role: STUDY_DIRECTOR